Literature DB >> 11399033

An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease.

X He1, F Chen, S Gatt, E H Schuchman.   

Abstract

Sphingomyelin is an important lipid component of cell membranes and lipoproteins which can be hydrolyzed by sphingomyelinases into ceramide and phosphorylcholine. The type A and B forms of Niemann-Pick disease (NPD) are lipid storage disorders due to the deficient activity of the enzyme acid sphingomyelinase, and the resultant accumulation of sphingomyelin in cells and tissues. In this paper we report a new, enzyme-based method to quantify the levels of sphingomyelin in tissues and plasma of normal individuals and NPD patients. The method utilizes sphingomyelinase from Bacillus cereus to completely hydrolyze the sphingomyelin into ceramide. Quantification of the sphingomyelin-derived ceramide is accomplished using Escherichia coli diacylglycerol (DAG) kinase and [gamma-(32)P]ATP. The resulting [(32)P]ceramide is quantified using a phosphor-imager system following TLC separation. This procedure allowed quantification of sphingomyelin over a broad range from 10 pmol to 1 nmol. To validate this assay we quantified sphingomyelin in plasma and tissues obtained from normal and NPD mice and humans. The sphingomyelin content in adult homozygous (-/-) or heterozygous (+/-) NPD mouse plasma was significantly elevated compared to that of normal mice (up to twofold). Moreover, the accumulated sphingomyelin in the tissues of NPD mice was 4 to 40 times higher than that in normal mice depending on the tissue analyzed. The sphingomyelin levels in plasma from several type B NPD patients also were significantly elevated compared to normal individuals of the same age. Based on these results we propose that this new, enzyme-based procedure can provide sensitive and reproducible sphingomyelin quantification in tissues and fluids from normal individuals and NPD patients. It could be a useful tool for the diagnosis of NPD and the evaluation of NPD treatment protocols, as well as for the study of ceramide-mediated apoptosis since the method provides the simultaneous determination of sphingomyelin and ceramide in the same lipid extract. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399033     DOI: 10.1006/abio.2001.5108

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

Authors:  Raymond Y Wang; Afshin Aminian; Michael F McEntee; Shih-Hsin Kan; Calogera M Simonaro; William C Lamanna; Roger Lawrence; N Matthew Ellinwood; Catalina Guerra; Steven Q Le; Patricia I Dickson; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2014-06-06       Impact factor: 4.797

2.  Highlighting anatomical sub-structures in rat brain tissue using lipid imaging.

Authors:  Alice M Delvolve; Benoit Colsch; Amina S Woods
Journal:  Anal Methods       Date:  2011-08-01       Impact factor: 2.896

3.  Identification of cystatin SA as a novel inhibitor of acid ceramidase.

Authors:  Efrat Eliyahu; Nataly Shtraizent; Xingxuan He; Dafna Chen; Ruth Shalgi; Edward H Schuchman
Journal:  J Biol Chem       Date:  2011-08-16       Impact factor: 5.157

4.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

5.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

6.  Deregulation of sphingolipid metabolism in Alzheimer's disease.

Authors:  Xingxuan He; Yu Huang; Bin Li; Cheng-Xin Gong; Edward H Schuchman
Journal:  Neurobiol Aging       Date:  2008-06-10       Impact factor: 4.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.